Company Modalis Therapeutics Corporation

Equities

4883

JP3922600006

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
77 ^JPY	0.00%		-1.28%	-37.90%

Apr. 15	Modalis Therapeutics to See Reduced Expenses of 250 to 350 Million After Cutting Jobs	MT
Feb. 23	Modalis Therapeutics to Reduce Stated Capital and Capital Reserves	MT

Modalis Therapeutics Corp is a Japan-based company engaged in the research and development of gene therapy drugs using the core platform CRISPR-GNDM technology. The Company develops gene therapy drugs that use CRISPR-GNDM technology, which is a unique platform technology, for genetic diseases caused by errors in the genetic code and epigenetics. The Company has two business models. Collaborative model pipeline opens CRISPR-GNDM technology to partners, and develops therapeutic drugs with partners' funds for the targets selected by the partners. In-house model pipeline selects targets using the Company's own CRISPR-GNDM technology and develops therapeutic agents. The Company's pipeline consists of a collaborative model pipeline of 5 items such as MDL-201 and an in-house model pipeline of 2 items such as MDL-101.

Number of employees: 37

Managers	Title	Age	Since
Haru Morita FOU	Founder	54	15-12-31
Naoki Kobayashi DFI	Director of Finance/CFO	60	-
Tetsuya Yamagata CTO	Chief Tech/Sci/R&D Officer	-	-

Members of the board	Title	Age	Since
Joseph McCracken BRD	Director/Board Member	70	18-07-31
Toshio Furuta BRD	Director/Board Member	62	18-11-30
Haru Morita FOU	Founder	54	15-12-31
Teruhisa Tajima BRD	Director/Board Member	52	15-12-31
Hideki Takeda BRD	Director/Board Member	65	15-12-31
Osamu Nureki FOU	Founder	58	15-12-31
Miyuki Shimane BRD	Director/Board Member	70	18-11-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	36,795,206	30,684,543 ( 83.39 %)	63 ( 0.000171 %)	83.39 %

Name	Equities	%	Valuation
Haru Morita 15.36 %	5,194,500	15.36 %	3 M ¥
Osamu Nureki 7.560 %	2,556,100	7.560 %	2 M ¥
Rheos Capital Works, Inc. (Investment Management) 4.126 %	1,395,000	4.126 %	884 862 ¥
SBI Investment Co., Ltd. 3.494 %	1,181,400	3.494 %	749 374 ¥
Fast Track Initiative, Inc. 2.037 %	688,800	2.037 %	436 913 ¥
UTokyo Innovation Platform Co.,Ltd. 1.494 %	505,300	1.494 %	320 517 ¥
Hideki Takeda 0.5717 %	193,300	0.5717 %	122 612 ¥
Chibagin Asset Management Co. Ltd. 0.4356 %	147,300	0.4356 %	93 434 ¥
CARENET, INC. 0.2958 %	100,000	0.2958 %	63 431 ¥
Teruhisa Tajima 0.2958 %	100,000	0.2958 %	63 431 ¥

Modalis Therapeutics Corp.

Y's Building, 4/F 16-5 Nihonbashikabutocho

103-0026, Tokyo

http://www.modalistx.com/jp/

address Modalis Therapeutics Corporation(4883)

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
MODALIS THERAPEUTICS CORPORATION	-37.90%	16.73M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+0.87%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-8.19%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs